CO2021010380A2 - Pharmaceutical compositions comprising meloxicam - Google Patents
Pharmaceutical compositions comprising meloxicamInfo
- Publication number
- CO2021010380A2 CO2021010380A2 CONC2021/0010380A CO2021010380A CO2021010380A2 CO 2021010380 A2 CO2021010380 A2 CO 2021010380A2 CO 2021010380 A CO2021010380 A CO 2021010380A CO 2021010380 A2 CO2021010380 A2 CO 2021010380A2
- Authority
- CO
- Colombia
- Prior art keywords
- meloxicam
- migraine
- rizatriptan
- pain
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
RESUMEN DE LA INVENCIÓN Se describe en la presente composiciones que comprenden un NSAID como meloxicam y/o rizatriptan en combinación con una ciclodextrina y/o un carbonato o un bicarbonato. Estas composiciones pueden ser oralmente administradas, por ejemplo, para mejorar la biodisponibilidad o farmacocinéticas del NSAID para el tratamiento de dolor como migraña, artritis, y otras afecciones. También se describen aquí métodos para tratar el dolor, como migraña, que comprenden administrar meloxicam y rizatriptan a un ser humano que sufre de dolor, como migraña. Para la migraña, estos métodos pueden ser particularmente útiles cuando el meloxicam y el rizatriptan son administrados mientras el ser humano está sufriendo de un ataque agudo de dolor de migraña o aura de migraña. En algunas modalidades, la combinación de meloxicam y rizatriptan pueden ser administrados en una forma que resulta en una Tmax de meloxicam de 3 horas o menos.SUMMARY OF THE INVENTION Compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate are described herein. These compositions can be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also described herein are methods of treating pain, such as migraine, which comprise administering meloxicam and rizatriptan to a human suffering from pain, such as migraine. For migraine, these methods can be particularly useful when meloxicam and rizatriptan are administered while the human is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan can be administered in a manner that results in a meloxicam Tmax of 3 hours or less.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962802198P | 2019-02-06 | 2019-02-06 | |
US201962803756P | 2019-02-11 | 2019-02-11 | |
US201962835613P | 2019-04-18 | 2019-04-18 | |
US201962846311P | 2019-05-10 | 2019-05-10 | |
US201962860705P | 2019-06-12 | 2019-06-12 | |
US201962895956P | 2019-09-04 | 2019-09-04 | |
US201962895933P | 2019-09-04 | 2019-09-04 | |
US201962955905P | 2019-12-31 | 2019-12-31 | |
PCT/US2020/017046 WO2020163620A1 (en) | 2019-02-06 | 2020-02-06 | Pharmaceutical compositions comprising meloxicam |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021010380A2 true CO2021010380A2 (en) | 2021-09-30 |
Family
ID=71947112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0010380A CO2021010380A2 (en) | 2019-02-06 | 2021-08-06 | Pharmaceutical compositions comprising meloxicam |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP3920909A4 (en) |
JP (3) | JP7237386B2 (en) |
KR (1) | KR20210118880A (en) |
CN (1) | CN113423397A (en) |
AU (2) | AU2020218253B2 (en) |
BR (1) | BR112021015467A2 (en) |
CA (2) | CA3213549A1 (en) |
CL (1) | CL2021002070A1 (en) |
CO (1) | CO2021010380A2 (en) |
CR (1) | CR20210420A (en) |
EC (1) | ECSP21060962A (en) |
IL (1) | IL285389A (en) |
MA (1) | MA54904A (en) |
MX (1) | MX2021009435A (en) |
PE (1) | PE20212157A1 (en) |
SG (1) | SG11202107926XA (en) |
WO (1) | WO2020163620A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2024502041A (en) * | 2020-12-31 | 2024-01-17 | アクスサム セラピューティクス インコーポレイテッド | Pharmaceutical compositions containing meloxicam |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1126841B1 (en) * | 1998-11-02 | 2004-12-15 | Merck & Co., Inc. | Combinations of a 5ht1b/1d agonist and a selective cox-2 inhibitor for the treatment of migraine |
US20040214861A1 (en) * | 2003-03-28 | 2004-10-28 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine |
US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
US20090068262A1 (en) * | 2007-04-04 | 2009-03-12 | Ilan Zalit | Rapid dissolution of combination products |
ES2769949T3 (en) * | 2009-05-13 | 2020-06-29 | Cydex Pharmaceuticals Inc | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of preparing and using them |
US9821075B2 (en) * | 2015-02-10 | 2017-11-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
AU2016218992C1 (en) * | 2015-02-10 | 2019-09-26 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
SI3256138T1 (en) * | 2015-11-25 | 2022-07-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
CN109952314A (en) * | 2016-09-23 | 2019-06-28 | 泰瓦制药国际有限公司 | Treat intractable migraine |
PT3565550T (en) * | 2017-01-04 | 2021-01-20 | Axsome Therapeutics Inc | Pharmaceutical compositions comprising meloxicam |
US10471014B2 (en) * | 2017-01-04 | 2019-11-12 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
CN110612103B (en) * | 2017-05-10 | 2023-08-22 | 艾克萨姆治疗公司 | Pharmaceutical composition comprising meloxicam |
-
2020
- 2020-02-06 KR KR1020217026519A patent/KR20210118880A/en not_active Application Discontinuation
- 2020-02-06 SG SG11202107926XA patent/SG11202107926XA/en unknown
- 2020-02-06 EP EP20752178.2A patent/EP3920909A4/en active Pending
- 2020-02-06 CR CR20210420A patent/CR20210420A/en unknown
- 2020-02-06 PE PE2021001288A patent/PE20212157A1/en unknown
- 2020-02-06 WO PCT/US2020/017046 patent/WO2020163620A1/en unknown
- 2020-02-06 JP JP2021545919A patent/JP7237386B2/en active Active
- 2020-02-06 CN CN202080012487.9A patent/CN113423397A/en active Pending
- 2020-02-06 MX MX2021009435A patent/MX2021009435A/en unknown
- 2020-02-06 BR BR112021015467-1A patent/BR112021015467A2/en unknown
- 2020-02-06 CA CA3213549A patent/CA3213549A1/en active Pending
- 2020-02-06 CA CA3128940A patent/CA3128940C/en active Active
- 2020-02-06 MA MA054904A patent/MA54904A/en unknown
- 2020-02-06 AU AU2020218253A patent/AU2020218253B2/en active Active
-
2021
- 2021-08-04 IL IL285389A patent/IL285389A/en unknown
- 2021-08-05 CL CL2021002070A patent/CL2021002070A1/en unknown
- 2021-08-06 CO CONC2021/0010380A patent/CO2021010380A2/en unknown
- 2021-08-17 EC ECSENADI202160962A patent/ECSP21060962A/en unknown
-
2023
- 2023-02-21 JP JP2023025218A patent/JP7420990B2/en active Active
- 2023-04-27 AU AU2023202545A patent/AU2023202545A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002855A patent/JP2024026732A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2021009435A (en) | 2021-09-10 |
EP3920909A4 (en) | 2022-11-30 |
MA54904A (en) | 2021-12-15 |
WO2020163620A1 (en) | 2020-08-13 |
ECSP21060962A (en) | 2021-11-30 |
EP3920909A1 (en) | 2021-12-15 |
JP2023062144A (en) | 2023-05-02 |
JP2022519670A (en) | 2022-03-24 |
AU2020218253A1 (en) | 2021-08-12 |
CA3128940A1 (en) | 2020-08-13 |
SG11202107926XA (en) | 2021-08-30 |
CR20210420A (en) | 2021-12-22 |
JP2024026732A (en) | 2024-02-28 |
AU2020218253B2 (en) | 2023-02-23 |
JP7237386B2 (en) | 2023-03-13 |
IL285389A (en) | 2021-09-30 |
CN113423397A (en) | 2021-09-21 |
BR112021015467A2 (en) | 2021-10-05 |
JP7420990B2 (en) | 2024-01-23 |
AU2023202545A1 (en) | 2023-05-18 |
CA3128940C (en) | 2023-11-07 |
PE20212157A1 (en) | 2021-11-09 |
KR20210118880A (en) | 2021-10-01 |
CL2021002070A1 (en) | 2022-04-01 |
CA3213549A1 (en) | 2020-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021002099A1 (en) | Pharmaceutical combination comprising tno155 and ribociclib. | |
CR20210061A (en) | Pharmaceutical compositions comprising meloxicam | |
EA201691454A1 (en) | COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING | |
CO6341486A2 (en) | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | |
CO6531463A2 (en) | COMBINATIONS OF A PI3K INHIBITOR AND A MEK INHIBITOR | |
MX2022003072A (en) | Use of pridopidine for treating functional decline. | |
CL2018001677A1 (en) | Treatment of fabry disease in patients not treated and previously treated with ert | |
CL2020001742A1 (en) | Glycolate oxidase inhibitors for the treatment of diseases | |
BR112015026297A2 (en) | combination therapy consisting of a tor kinase inhibitor and a substituted 5-quinazolinone compound for cancer treatment | |
BR112015018360A2 (en) | Combination therapy for the treatment of nosocomial pneumonia | |
CO2021001472A2 (en) | Transglutaminase 2 (tg2) inhibitors | |
CL2019000190A1 (en) | Treatment and prevention of sleep disorders. | |
BR112018008186A2 (en) | Methods That Use Whey Protein To Improve Or Maintain Muscle Quality | |
BR112017006425B8 (en) | COMPOUNDS DERIVED FROM ISOXAZOLE, THEIR USES, INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASE 1 AND THE PRODUCTION OF D-2 HYDROXYGLUTAMATE, ANTITUMORAL AGENT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
CO2021010380A2 (en) | Pharmaceutical compositions comprising meloxicam | |
CO2020004034A2 (en) | Methods for the treatment of muscular dystrophy | |
CO2020015377A2 (en) | Modulators of apol1 expression | |
CL2018000430A1 (en) | Hydroxytriazine compound and related medical use. | |
CO2021014024A2 (en) | Methods for treating muscular dystrophy with casimersin | |
AR113983A1 (en) | TREATMENT OF AUTONOMOUS DISORDERS | |
CL2020000859A1 (en) | Gluconic acid derivatives to be used in the treatment and / or prevention of microbial infections. | |
MX2018015208A (en) | Andrographolide treats progressive forms of multiple sclerosis. | |
BR112018007399A2 (en) | composition, method of treatment, part kit and dosage form | |
MX2021003651A (en) | Formulation comprising ozonised oil in the treatment of a tumour. | |
AR114306A1 (en) | TREATMENT AND PREVENTION OF SLEEP DISORDERS |